Redhill Biopharma Stock Piotroski F Score
| RDHL Stock | USD 6.78 0.04 0.59% |
Redhill |
At this time, it appears that Redhill Biopharma's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
0.0
Piotroski F Score - Poor
| Current Return On Assets | N/A |
| Change in Return on Assets | N/A |
| Cash Flow Return on Assets | N/A |
| Current Quality of Earnings (accrual) | N/A |
| Asset Turnover Growth | N/A |
| Current Ratio Change | N/A |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | N/A |
| Change in Gross Margin | N/A |
Redhill Biopharma Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Redhill Biopharma is to make sure Redhill is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Redhill Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Redhill Biopharma's financial numbers are properly reported.
About Redhill Biopharma Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.About Redhill Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Redhill Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Redhill Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Redhill Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Redhill Biopharma Altman Z Score, Redhill Biopharma Correlation, Redhill Biopharma Valuation, as well as analyze Redhill Biopharma Alpha and Beta and Redhill Biopharma Hype Analysis. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.